Most Say Tensions Between Trump Administration and News Media Hinder Access to Political News

According to a new Pew Research Center survey, 94% of Americans say they have heard about the current state of the relationship between the Trump administration and the news media. And what they've seen does not reassure them: Large majorities feel the relationship is unhealthy and that the ongoing tensions are impeding Americans' access to important political news. Moreover, both of these concerns are widely shared across nearly all demographic groups, including large majorities of both Democrats and Republicans

The Modern News Consumer: News Attitudes and Practices in the Digital Era

Wave after wave of digital innovation has introduced a new set of influences on the public's news habits. Social media, messaging apps, texts and email provide a constant stream of news from people we're close to as well as total strangers. News stories can now come piecemeal, as links or shares, putting less emphasis on the publisher. And, hyper levels of immediacy and mobility can create an expectation that the news will come to us whether we look for it or not. How have these influences shaped Americans' appetite for and attitudes toward the news? What, in other words, are the defining traits of the modern news consumer?A new, two-part survey by Pew Research Center, conducted in early 2016 in association with the John S. and James L. Knight Foundation, reveals a public that is cautious as it moves into this more complex news environment and discerning in its evaluation of available news sources.To be sure, news remains an important part of public life. More than seven-in-ten U.S. adults follow national and local news somewhat or very closely – 65% follow international news with the same regularity. Fully 81% of Americans get at least some of this news through websites, apps or social networking sites. And, this digital news intake is increasingly mobile. Among those who get news both on desktop computers and mobile devices, more than half prefer mobile.In this digital news environment, the role of friends and family is amplified, but Americans still reveal strong ties to news organizations. The data also reinforce how, despite the dramatic changes witnessed over the last decade, the digital news era is still very much in its adolescence.These findings come from a two-part study which asked U.S. adults a wide range of questions about their news habits and attitudes, and then over the course of a subsequent week asked them in real time about news they had gotten in the last two hours. The first survey was conducted Jan. 12-Feb. 8, 2016, among 4,654 U.S. adults ages 18 and older who are members of Pew Research Center's American Trends Panel. The second survey consisted of 14 short, online surveys that were administered two per day from Feb. 24-March 1, 2016. Survey invitations were sent at different times each day, and responses were accepted for two hours after the invitations were sent. Panelists who completed the January wave on the web and reported that they get news online were asked to participate in the experiential study; 2,078 panelists participated and completed at least 10 of the 14 surveys

Journalists Sense Turmoil in Their Industry Amid Continued Passion for Their Work

Much of Pew Research Center's earlier research on the U.S. news environment has focused on the public's news consumption habits and views toward the news media. This major new undertaking was designed to capture the other side of the equation, asking U.S.-based journalists to provide their own perspective on the industry they work in.The main source of data for this study is a Pew Research Center survey of 11,889 U.S.-based journalists who are currently working in the news industry and said that they report, edit or create original news stories in their current job. The survey was conducted online between Feb. 16 and March 17, 2022.

Bioactivity of Dental Restorative Materials: FDI Policy Statement.

The term bioactivity is being increasingly used in medicine and dentistry. Due to its positive connotation, it is frequently utilised for advertising dental restorative materials. However, there is confusion about what the term means, and concerns have been raised about its potential overuse. Therefore, FDI decided to publish a Policy Statement about the bioactivity of dental restorative materials to clarify the term and provide some caveats for its use in advertising. Background information for this Policy Statement was taken from the current literature, mainly from the PubMed database and the internet. Bioactive restorative materials should have beneficial/desired effects. These effects should be local, intended, and nontoxic and should not interfere with a material's principal purpose, namely dental tissue replacement. Three mechanisms for the bioactivity of such materials have been identified: purely biological, mixed biological/chemical, or strictly chemical. Therefore, when the term bioactivity is used in an advertisement or in a description of a dental restorative material, scientific evidence (in vitro or in situ, and preferably in clinical studies) should be provided describing the mechanism of action, the duration of the effect (especially for materials releasing antibacterial substances), and the lack of significant adverse biological side effects (including the development and spread of antimicrobial resistance). Finally, it should be documented that the prime purpose, for instance, to be used to rebuild the form and function of lost tooth substance or lost teeth, is not impaired, as demonstrated by data from in vitro and clinical studies. The use of the term bioactive dental restorative material in material advertisement/information should be restricted to materials that fulfil all the requirements as described in the FDI Policy Statement

Оцінка фінансового стану підприємства

QC 20160518</p

Western Kentucky University Libraries, Preparing Information Literate Students at WKU: Report of the Task Force on Universal Information Literacy

Purpose: The Task Force on Universal Information Literacy was formed in the fall of 2010 and charged with reviewing the advisability and viability of providing information literacy instruction to every student at WKU

Design and Implementation of a Studio-Based General Chemistry Course

Most students taking general chemistry courses do not intend to pursue careers in chemistry; in fact, they are more likely to end up in positions where they fund, write, or vote for chemical research and policies. Our profession continues to ask how we can teach students scientific reasoning skills and chemical understanding in general chemistry that they are able to take beyond the classroom into their everyday lives. The emerging answer at this university is the studio teaching method, which incorporates the “best teaching and learning practices†recommended by chemical education research within an integrated lecture–lab technology-intensive environment. The design, implementation, and pedagogical rationale of studio general chemistry are described

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Background: Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity. In this trial we assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma. Methods: In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited patients from 87 hospitals and cancer centres across 11 countries. Eligible patients were aged 18 years or older, had a platinum-sensitive, high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube carcinoma, had received at least two previous platinum-based chemotherapy regimens, had achieved complete or partial response to their last platinum-based regimen, had a cancer antigen 125 concentration of less than the upper limit of normal, had a performance status of 0–1, and had adequate organ function. Patients were ineligible if they had symptomatic or untreated central nervous system metastases, had received anticancer therapy 14 days or fewer before starting the study, or had received previous treatment with a poly(ADP-ribose) polymerase inhibitor. We randomly allocated patients 2:1 to receive oral rucaparib 600 mg twice daily or placebo in 28 day cycles using a computer-generated sequence (block size of six, stratified by homologous recombination repair gene mutation status, progression-free interval after the penultimate platinum-based regimen, and best response to the most recent platinum-based regimen). Patients, investigators, site staff, assessors, and the funder were masked to assignments. The primary outcome was investigator-assessed progression-free survival evaluated with use of an ordered step-down procedure for three nested cohorts: patients with BRCA mutations (carcinoma associated with deleterious germline or somatic BRCA mutations), patients with homologous recombination deficiencies (BRCA mutant or BRCA wild-type and high loss of heterozygosity), and the intention-to-treat population, assessed at screening and every 12 weeks thereafter. This trial is registered with ClinicalTrials.gov, number NCT01968213; enrolment is complete. Findings: Between April 7, 2014, and July 19, 2016, we randomly allocated 564 patients: 375 (66%) to rucaparib and 189 (34%) to placebo. Median progression-free survival in patients with a BRCA-mutant carcinoma was 16·6 months (95% CI 13·4–22·9; 130 [35%] patients) in the rucaparib group versus 5·4 months (3·4–6·7; 66 [35%] patients) in the placebo group (hazard ratio 0·23 [95% CI 0·16–0·34]; p&lt;0·0001). In patients with a homologous recombination deficient carcinoma (236 [63%] vs 118 [62%]), it was 13·6 months (10·9–16·2) versus 5·4 months (5·1–5·6; 0·32 [0·24–0·42]; p&lt;0·0001). In the intention-to-treat population, it was 10·8 months (8·3–11·4) versus 5·4 months (5·3–5·5; 0·36 [0·30–0·45]; p&lt;0·0001). Treatment-emergent adverse events of grade 3 or higher in the safety population (372 [99%] patients in the rucaparib group vs 189 [100%] in the placebo group) were reported in 209 (56%) patients in the rucaparib group versus 28 (15%) in the placebo group, the most common of which were anaemia or decreased haemoglobin concentration (70 [19%] vs one [1%]) and increased alanine or aspartate aminotransferase concentration (39 [10%] vs none). Interpretation: Across all primary analysis groups, rucaparib significantly improved progression-free survival in patients with platinum-sensitive ovarian cancer who had achieved a response to platinum-based chemotherapy. ARIEL3 provides further evidence that use of a poly(ADP-ribose) polymerase inhibitor in the maintenance treatment setting versus placebo could be considered a new standard of care for women with platinum-sensitive ovarian cancer following a complete or partial response to second-line or later platinum-based chemotherapy. Funding: Clovis Oncology

The unstructured C-terminus of the τ subunit of Escherichia coli DNA polymerase III holoenzyme is the site of interaction with the α subunit

The τ subunit of Escherichia coli DNA polymerase III holoenzyme interacts with the α subunit through its C-terminal Domain V, τC16. We show that the extreme C-terminal region of τC16 constitutes the site of interaction with α. The τC16 domain, but not a derivative of it with a C-terminal deletion of seven residues (τC16Δ7), forms an isolable complex with α. Surface plasmon resonance measurements were used to determine the dissociation constant (KD) of the α−τC16 complex to be ∼260 pM. Competition with immobilized τC16 by τC16 derivatives for binding to α gave values of KD of 7 μM for the α−τC16Δ7 complex. Low-level expression of the genes encoding τC16 and τC16▵7, but not τC16Δ11, is lethal to E. coli. Suppression of this lethal phenotype enabled selection of mutations in the 3′ end of the τC16 gene, that led to defects in α binding. The data suggest that the unstructured C-terminus of τ becomes folded into a helix–loop–helix in its complex with α. An N-terminally extended construct, τC24, was found to bind DNA in a salt-sensitive manner while no binding was observed for τC16, suggesting that the processivity switch of the replisome functionally involves Domain IV of τ